Market Overview

Insulet Downgraded Despite Expectations For Strong Performance

Insulet Downgraded Despite Expectations For Strong Performance
Related PODD
Benzinga's Daily Biotech Pulse: FDA Nods For Teligent And Keytruda, Sonoma's Q4 Miss, Sage Inks Deal With Japan's Shionogi
Benzinga's Daily Biotech Pulse: vTv Swoons On Failed Alzheimer's Trial, Regenxbio Gets FDA Fast Track For RGX-111
FDA OKs Tandem's t:slim X2 insulin pump with hypoglycemia management feature; shars up 1% after hours (Seeking Alpha)

After a strong run that sent shares of Insulet Corporation (NASDAQ: PODD) up 50 percent over the last year, BTIG analyst Sean Lavin finally sees shares as fairly valued. This pushed him to downgrade Insulet to a Neutral rating.

“We do not feel a reasonable revenue multiple would provide us with a price target with another 15% of upside from here and thus our rating must move to Neutral," Lavin wrote in a note. "This said, management seemed very confident at ADA and as we mention in our preview today, a strong Q2 would not surprise us."

All About The Valuation

Lavin is still very confident in Insulet’s management team as they continue to beat his expectations.

“Our downgrade is entirely based on valuation, with PODD currently trading at ~6.5x EV/Sales on a next twelve month basis, just over 1 standard deviation over its historical average of 5.4x,” he noted.

Shares of Insulet were down 1.46 percent at $49.97 during Monday’s trading session.

To read the latest and exclusive financial news, check out the Benzinga Pro news wire.

Latest Ratings for PODD

Jun 2018Morgan StanleyMaintainsEqual-WeightEqual-Weight
May 2018Canaccord GenuityMaintainsBuyBuy
May 2018BMO CapitalMaintainsOutperformOutperform

View More Analyst Ratings for PODD
View the Latest Analyst Ratings

Posted-In: btig Sean LavinAnalyst Color Downgrades Analyst Ratings Best of Benzinga


Related Articles (PODD)

View Comments and Join the Discussion!